Chemistry:Devazepide
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H20N4O2 |
| Molar mass | 408.461 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Devazepide[1] (L-364,718, MK-329) is benzodiazepine drug, but with quite different actions from most benzodiazepines, lacking affinity for GABAA receptors and instead acting as an CCKA receptor antagonist.[2] It increases appetite and accelerates gastric emptying,[3][4] and has been suggested as a potential treatment for a variety of gastrointestinal problems including dyspepsia, gastroparesis and gastric reflux.[5] It is also widely used in scientific research into the CCKA receptor.[6][7]
Synthesis
Devazepide is synthesised in a similar manner to other benzodiazepines.[8][9]
See also
- Benzodiazepine
- Cholecystokinin antagonist
References
- ↑ Evans, Ben E.; Roger M. Freidinger & Mark G. Bock, "Benzodiazepine analogs", US patent 4820834, published 1989-04-11
- ↑ "Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260". Brain Research 526 (2): 276–83. September 1990. doi:10.1016/0006-8993(90)91232-6. PMID 2257485.
- ↑ "Multiple cholecystokinin (CCK) receptors and CCK-monoamine interactions are instrumental in the control of feeding". Physiology & Behavior 48 (6): 849–57. December 1990. doi:10.1016/0031-9384(90)90239-z. PMID 1982361.
- ↑ "CCK antagonists and CCK-monoamine interactions in the control of satiety". The American Journal of Clinical Nutrition 55 (1 Suppl): 291S–295S. January 1992. doi:10.1093/ajcn/55.1.291s. PMID 1728842.
- ↑ "Effect of CCK and its antagonists on gastric emptying". Journal of Physiology, Paris 87 (5): 291–300. 1993. doi:10.1016/0928-4257(93)90035-r. PMID 8298606.
- ↑ "The ontogeny of postingestive inhibitory stimuli: examining the role of CCK". Developmental Psychobiology 48 (5): 368–79. July 2006. doi:10.1002/dev.20148. PMID 16770766.
- ↑ "Intestinal nutrients elicit satiation through concomitant activation of CCK(1) and 5-HT(3) receptors". Physiology & Behavior 92 (3): 434–42. October 2007. doi:10.1016/j.physbeh.2007.04.017. PMID 17531277.
- ↑ "Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists". Journal of Medicinal Chemistry 31 (12): 2235–46. December 1988. doi:10.1021/jm00120a002. PMID 2848124.
- ↑ Jackson, Karen, "The use of devazepide as analgesic agent", EP patent 1492540, published 2005-01-05
 |  |
